Feed EMPD
Summary
36 / 100 · Bulios Score
Valuation 100Growth 22Profitability 2Quality 15Debt 40Stability 44
What speaks for it
- It bought back its own shares for $96.3M in the last fiscal year, 117% of its market value.
What to watch
- Revenue fell by 40% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
Revenue fell by 40% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $272.1M.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $3.59M
Debt $55.6M
Free cash flow over 12 months -$472.7M
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Today's price within the analysts' price targets
Today's price $2.92 Average target $6
$2.92 $6
The average target of $6 is 105% above today's price.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.